Patents by Inventor Martin G. Pomper

Martin G. Pomper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180009767
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: June 9, 2017
    Publication date: January 11, 2018
    Applicants: THE JOHNS HOPKINS UNIVERSITY, INTUITIVE SURGICAL OPERATIONS, INC.
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, SANGEETA RAY, JONATHAN SORGER
  • Patent number: 9861713
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: January 9, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie Charles Mease, Ying Chen
  • Publication number: 20170333576
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 23, 2017
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, SANGEETA RAY, YING CHEN, XING YANG
  • Publication number: 20170290930
    Abstract: The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to C3d (mAB 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a Mycobacterium tuberculosis (M. tuberculosis) infection in a subject, as well as methods of treating a M. tuberculosis infection in a subject.
    Type: Application
    Filed: September 15, 2015
    Publication date: October 12, 2017
    Inventors: Martin G. Pomper, Catherine A. Foss, Joshua M. Thurman, V. Michael Holers
  • Publication number: 20170283384
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 5, 2017
    Applicants: THE JOHNS HOPKINS UNIVERSITY, INTUITIVE SURGICAL OPERATIONS, INC.
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, SANGEETA RAY, JONATHAN SORGER
  • Patent number: 9776977
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: October 3, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray
  • Publication number: 20170218464
    Abstract: The presently disclosed subject matter provides methods, reporter gene constructs, and kits for using prostate-specific membrane antigen (PSMA) as an imaging reporter to image a variety of cells and tissues.
    Type: Application
    Filed: March 18, 2015
    Publication date: August 3, 2017
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, MARK CASTANARES, IL MINN, SHAWN LUPOLD
  • Publication number: 20170202985
    Abstract: The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.
    Type: Application
    Filed: April 4, 2017
    Publication date: July 20, 2017
    Inventors: Martin G. Pomper, Richard F. Ambinder, Jun O. Liu, Curtis R. Chong, Jianmeng Chen
  • Patent number: 9694091
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: July 4, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Catherine Anne Foss
  • Publication number: 20170135961
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Application
    Filed: July 13, 2016
    Publication date: May 18, 2017
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Publication number: 20170081298
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Application
    Filed: May 6, 2015
    Publication date: March 23, 2017
    Applicants: THE JOHNS HOPKINS UNIVERSITY, NORTHWESTERN UNIVERSITY
    Inventors: SANGEETA RAY, MARTIN G. POMPER, THOMAS J. MEADE, RONNIE C. MEASE, YING CHEN, XING YANG, MATTHEW ROTZ
  • Publication number: 20170049912
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Application
    Filed: September 8, 2016
    Publication date: February 23, 2017
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, SANGEETA RAY, RONNIE C. MEASE, HASSAN SHALLAL
  • Publication number: 20160367708
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using aqueous 32P. In certain embodiments, the present invention provides a method for treating cancer in a patient comprising the step of intravenously administering a low dose of aqueous 32P monophosphate or 32P pyrophosphate to the patient.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 22, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: John Martin Abraham, Yulan Cheng, Martin G. Pomper, Stephen J. Meltzer, Joseph Herman
  • Publication number: 20160354498
    Abstract: The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.
    Type: Application
    Filed: March 17, 2016
    Publication date: December 8, 2016
    Inventors: Martin G. Pomper, Richard Ambinder, Jun O. Liu, Curtis R. Chong, Jianmeng Chen
  • Publication number: 20160331845
    Abstract: Compositions comprising a polymeric micellar nanoparticle composition comprising a block or graft copolymer comprising at least one polycationic polymer and at least one polyethylene glycol (PEG) polymer having an average molecular weight less than 1 kDa, and at least one nucleic acid, wherein the graft or block copolymer and at least one nucleic acid are complexed and condensed into a shaped micellar nanoparticle that is stable in biological media are disclosed. The presently disclosed subject matter also provides a method for preparing the presently disclosed polymeric micellar nanoparticle compositions, a method for targeting at least one metastatic cancer cell in a subject, and a method for treating a disease or condition using the presently disclosed polymeric micellar nanoparticle compositions.
    Type: Application
    Filed: May 13, 2016
    Publication date: November 17, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: HAI-QUAN MAO, JOHN MICHAEL WILLIFORD, MAANI ARCHANG, IL MINN, YONG REN, JOSE LUIS SANTOS, MARTIN G. POMPER
  • Publication number: 20160271274
    Abstract: Magnetic iron oxide nanoparticles (MIONs) having silica (SiMION) and gold-silica (AuSiMION) nanoshells, methods of their preparation, and their use in cancer imaging and therapy applications are disclosed.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 22, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: ROBERT IVKOV, LAUREN WOODARD, MARTIN G. POMPER
  • Patent number: 9422234
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: August 23, 2016
    Assignee: The Johns Hopkins University
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Publication number: 20160235865
    Abstract: Urea-based photosensitizers, which target prostate-specific membrane antigen (PSMA) for imaging and targeted therapy of PSMA-expressing tumors and cancers are disclosed.
    Type: Application
    Filed: October 14, 2014
    Publication date: August 18, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE MEASE, YING CHEN
  • Publication number: 20160114060
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Application
    Filed: January 4, 2016
    Publication date: April 28, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. POMPER, Ronnie Charles MEASE, Ying CHEN
  • Publication number: 20160108429
    Abstract: The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 21, 2016
    Inventors: Paul B. FISHER, Swadesh K. Das, Mitchell E. MENEZES, Devanand Sarkar, Martin G. POMPER